Search Results

You are looking at 141 - 149 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Abstracts From the NCCN 2022 Annual Conference

Results-Medicare linked database, a retrospective cohort study was conducted for men age >66 years diagnosed with less than T1c/T2a or T2 not-otherwise-specified incident prostate cancer with Gleason score of ≤6 or prostate specific antigen level of ≤10 ng

Full access

NCCN Task Force Report: Bone Health in Cancer Care

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi N. Kumar, Charles L. Shapiro, Andrew Shields, Matthew R. Smith, Sandy Srinivas, and Catherine H. Van Poznak

– 1801 . 151 Smith MR Kabbinavar F Saad F . Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer . J Clin Oncol 2005 ; 23 : 2918 – 2925 . 152 Mason MD Sydes MR Glaholm J

Full access

NCCN Molecular Testing White Paper: Effectiveness, Efficiency, and Reimbursement

Paul F. Engstrom, Mara G. Bloom, George Daniel Demetri, Phillip G. Febbo, William Goeckeler, Marc Ladanyi, Bryan Loy, Kate Murphy, Michael Nerenberg, Paul Papagni, Mark Robson, Robert W. Sweetman, Sean Tunis, Jessica DeMartino, and Jonathan K. Larsen

are most commonly used for risk assessment (e.g., germline mutation in BRCA1/2 ), early detection (e.g., prostate-specific antigen [PSA]), diagnosis/subclassification (e.g., leukemia fusion oncogenes), prognosis (Onco type DX, MammaPrint [Agendia

Full access

NCCN Task Force Report: Bone Health in Cancer Care

Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F. Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A. Podoloff, Sandy Srinivas, and Catherine H. Van Poznak

the effects of zoledronic acid on time to first bone metastasis in men with prostate cancer without bone metastases and a rising prostate-specific antigen (PSA) level despite ADT was terminated approximately halfway into accrual when interim analysis

Full access

Abstracts From the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

lower, leading to a reduced difference in total costs compared with patients treated with Vd. AB2017-81. Prostate-Specific Antigen Progression in Patients Treated With Abiraterone Acetate Plus Prednisone or Placebo Plus Prednisone and Correlation With

Full access

NCCN Task Force Report: mTOR Inhibition in Solid Tumors

Robert A. Figlin, Elizabeth Brown, Andrew J. Armstrong, Wallace Akerley, Al B. Benson III, Harold J. Burstein, David S. Ettinger, Phillip G. Febbo, Matthew G. Fury, Gary R. Hudes, Merrill S. Kies, Eunice L. Kwak, Robert J. Morgan Jr., Joanne Mortimer, Karen Reckamp, Alan P. Venook, Frank Worden, and Yun Yen

cytoplasmic Akt correlated with prostate-specific antigen (PSA) relapse after surgery in a multivariate analysis. A subsequent paper examined PTEN expression and Akt activation in tissue from men undergoing radical prostatectomy who were followed up for 5

Full access

Occult Primary

David S. Ettinger, Mark Agulnik, Justin M. M. Cates, Mihaela Cristea, Crystal S. Denlinger, Keith D. Eaton, Panagiotis M. Fidias, David Gierada, Jon P. Gockerman, Charles R. Handorf, Renuka Iyer, Renato Lenzi, John Phay, Asif Rashid, Leonard Saltz, Lawrence N. Shulman, Jeffrey B. Smerage, Gauri R. Varadhachary, Jonathan S. Zager, and Weining (Ken) Zhen

cervical lymph nodes, isolated inguinal adenopathy (SCC), poorly differentiated neuroendocrine carcinomas, men with blastic bone metastases and elevated prostate-specific antigen (PSA; adenocarcinoma), and patients with a single, small, and potentially

Full access

Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Mary B. Daly, Tuya Pal, Michael P. Berry, Saundra S. Buys, Patricia Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Friedman, Michael Goggins, Mollie L. Hutton, CGC, Beth Y. Karlan, Seema Khan, Catherine Klein, Wendy Kohlmann, CGC, Allison W. Kurian, Christine Laronga, Jennifer K. Litton, Julie S. Mak, LCGC, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Holly J. Pederson, Gwen Reiser, CGC, Leigha Senter-Jamieson, CGC, Kristen Mahoney Shannon, Rebecca Shatsky, Kala Visvanathan, Jeffrey N. Weitzel, Myra J. Wick, Kari B. Wisinski, Matthew B. Yurgelun, Susan D. Darlow, and Mary A. Dwyer

with prostate cancer had significantly decreased survival, compared with patients who were noncarriers (5 vs 16 years, respectively; P <.001). 88 This association remained statistically significant when controlling for race, age, prostate-specific

Full access

Abstracts From the NCCN 23rd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™

, “Gleason score”: NCCN and Dutch CPGs; “prostate-specific antigen density”: NCCN CPGs only; “Nomogram not otherwise specified”: Dutch CPGs only), values, and recommendations. Conclusions: The decision tree model and common vocabulary facilitated a